market growth mean
us market slow materi suggest
result could come consensu drive
conserv approach guidanc
street number look somewhat risk adjust remain
focus platform pipelin improv
boston result morn present second neuromod miss quarter
boston neuromodul result miss estim
global spinal cord stimul franchis grew estim boston us
busi revenu growth miss
estim growth repres pt momentum deceler
follow abbott neuromodul miss last week us
franchis declin second neuromod miss quarter rais question
market becom clear market slow
market growth could flat neg quarter could come
consensu still see path estim abbott boston
saw q/q declin respect adjust medtron
estim growth model suggest us market roughli
flat ww estim consensu
includ us revenu flat us growth view estim
somewhat risk-adjust sever reason
us estim impli q/q declin greater declin
abbott boston seen model medtron grow q/q note
q/q growth histor greater peer
given season fiscal fourth quarter coincid calendar
first quarter model impli hold market share y/i
quarter vs bp share captur
ww estim account annual revenu line
typic season seen first quarter annual
market growth gave guidanc color quarterli
momentum less use us estim impli pt
momentum deceler abbott boston saw pt
momentum deceler respect think reason
medic technolog unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
anniversari larg growth rate
manag relat commerci disrupt even though compani
anniversari new product launch
net contempl potenti manag relat
commerci disrupt think result could come consensu
expect commerci disrupt well understood stock may
fulli reflect market disrupt discuss
could drive recent market weak discuss last week
unclear abbott weak us result compani specif
indic broader market half major compani
report becom appar market slow unlik abbott
saw issu company-specif boston could pinpoint
sourc slowdown reiter expect long term doubl
digit growth market expect franchis ramp
result data increment product enhanc boston also note
take share market model impli case
estim boston lost pt share sequenti may result
off-fisc year boston attempt extrapol abbott
result pertain market weak dilig on-going note
first time sinc us launch major new
product launch industri year prior product launch may
impact price mix well demand stimul
addit growth rate slow materi
addit effect market
channel dilig suggest inventori dynam may impact
growth rate prior period
reimburs prior author pressur appear broad
base outsid california worker compens chang
impact result last
take market growth estim dilig need
adjust market model exhibit taken
conserv approach model mid-singl digit us growth
boston growth abbott estim
remain unchang materi adjust year estim
time given seen entir sector report dilig
uncov primari caus one quarter may repres baselin
model us market growth year
market dynam lead conserv guidanc
schedul report result provid guidanc current suspend
upon keith grossman appoint ceo may note prior
guidanc set us market growth assumpt
initi perceiv conserv halfway
market result appear prescient current
model annual sale includ us sale
growth suggest gain bp us share
annual basi sequenti share build throughout year similar
fashion maintain share grow line us market
would worth pt us growth revenu impli
guidanc rang extent manag took conserv
approach guid would impli bp share loss
upgrad thesi center better execut moreso platform pipelin
stori next year continu believ new platform launch pdn
nsrbp dataset catalyz growth histor preced suggest
investor attent shift forward quarter matter less market
growth outlook remain risk thesi
million
price target base multipl base case
ep line high growth larg cap peer see
multipl reflect abbott better peer top bottom line growth nutrit
recov china imf headwind fade aler stabil gradual return market
growth new product libr confirm mri launch mitraclip
inflect sustain organ growth profil medium term management execut
deal synergi margin grow per year support ep
base case valuat use price-to-earnings valuat larg cap peer
believ justifi given better top bottom line growth line high
growth peer
valu driver includ continu oper margin expans core abbott
combin cost synergi execut st jude aler organ growth
acceler driven devic product launch diabet ep structur heart
risk price target includ emerg market macro slowdown fx headwind
strengthen us dollar failur deliv synergi target and/or growth
acceler aler failur libr mitraclip drive top-line growth
price target base multipl base case
ep assum trade larg cap peer justifi superior emerg
growth margin expans opportun leverag profil line high
growth peer ew sustain execut support
acceler high singl digit large-cap growth stori recent build pipelin
program drive sale compound-annual-growth-rate oper margin remain
track bp annual improv next sever year drive mid-teen
risk price target includ unfavor legal develop increas competit
core de market competit product launch failur execut
plan pipelin program integr
price target reflect ep discount larg cap peer
see total return profil long-term profil mid-singl digit organ
growth bp margin expans high-singl digit ep growth
total return profil howev question durabl achiev
profil lead discount versu peer
risk price target includ materi competit landscap chang
db tavr dcb linq ii slowdown acceler emerg market iii
less repurchas activ materi acquisit
price target reflect sale estim
median valuat low growth high growth smid cap med-tech
risk price target includ commerci execut could disappoint and/or
new platform launch fail catalyz sale ii upstart competitor could
acquir and/or obtain fund launch take materi share iii market
